BusinessProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis PatientsBy Nasdaq OMXOct 27, 2016, 11:05 AM UTC
BusinessProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis PatientsBy Nasdaq OMXOct 27, 2016, 11:05 AM UTC
BusinessProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFCBy Nasdaq OMXSep 27, 2016, 11:00 AM UTC
BusinessProteostasis Therapeutics Announces Scientific Presentations on New Data at 30th Annual North American Cystic Fibrosis ConferenceBy Nasdaq OMXSep 22, 2016, 11:30 AM UTC
BusinessRaptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis PatientsBy Nasdaq OMXSep 7, 2016, 7:30 AM UTC
BusinessProQR to Present at Scientific and Investor Conferences in SeptemberBy Nasdaq OMXSep 6, 2016, 11:01 AM UTC
